A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Sunil Sharma, MD
Novelty Nobility
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of Michigan Hospitals
Ann Arbor, Michigan, United States
Recruiting - Case Comprehensive Cancer Center
Cleveland, Ohio, United States
Recruiting - Oregon Health & Science University
Portland, Oregon, United States
Recruiting - the University of Texas Md Anderson Cancer Center
Houston, Texas, United States
Recruiting - Next Virginia
Fairfax, Virginia, United States
Active, not recruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 3 Feb 2025
- Primary completion
- 30 Aug 2027
- Completion
- 31 Dec 2027
- Last update posted
- 23 Sept 2025
- Registered enrollment
- 67
- Registry id
- NCT06805825
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.